<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
  <title>Larry Bock - LinkedIn </title>
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
  <link href="http://www.linkedin.com/favicon.ico" rel="shortcut icon" type="image/ico"></link>
  
    <meta name="description" content="View Larry Bock's professional profile on LinkedIn.  LinkedIn is the world's largest business network, helping professionals like Larry Bock discover inside connections to recommended job candidates, industry experts, and business partners." />
  
      <link rel="stylesheet" type="text/css" href="http://static.linkedin.com/scds/pprofile/build-502_6_2523-prod/css/public-profile/default.css">
    
</head>
<body id="www-linkedin-com" class="en public-profile">

<script type="text/javascript">document.body.className += " js";</script>
  
<div class="hresume">
    <div class="profile-header">
      <div class="masthead vcard contact portrait">
        <div id="nameplate">
          <h1 id="name"><span class="fn n"><span class="given-name">Larry</span> <span class="family-name">Bock</span></span></h1>
        </div>
        <div class="content">
          <div class="info">
              <div class="image"><img src="http://media.linkedin.com/mpr/mpr/shrink_80_80/p/2/000/000/293/106a5ab.jpg" class="photo" alt="Larry Bock" /></div>
              <p class="headline title">
                
      Executive Director at USA Science Festival
    
              </p>
            <div class="adr">
              <p class="locality">
                
      Greater San Diego Area
    
              </p>
            </div>
          </div>
          <div class="actions">
            <ul>
              <li id="send-inmail">
                <a href="http://www.linkedin.com/ppl/webprofile?action=ctu&amp;id=9739295&amp;pvs=pp&amp;authToken=_7_t&amp;authType=name&amp;trk=ppro_cntdir&amp;lnk=cnt_dir" rel="nofollow">Contact Larry Bock</a>
              </li>
              <li id="add-to-network">
                <a href="http://www.linkedin.com/ppl/webprofile?action=ctu&amp;id=9739295&amp;pvs=pp&amp;authToken=_7_t&amp;authType=name&amp;trk=ppro_getintr&amp;lnk=cnt_dir" rel="nofollow">Add Larry Bock to your network</a>
              </li>
            </ul>
          </div>
        </div>
      </div>
    </div>
  <div id="main">
        <div id="overview">
          <dl>
              <dt>Current</dt>
              <dd>
                <ul class="current">
                        <li>




            
      Executive Director
    
 at USA Science Festival

                        </li>
                        <li>




            
      Judge
    
 at UC San Diego Entrepreneur Challenge

                        </li>
                        <li>




            
      Judge
    
 at UC San Diego Entrepreneur Challenge

                        </li>
                </ul>
                  <div class="showhide-block" id="morecurr">
                    <ul class="current">
                            <li>




            
      Judge- Entrepreneurship Challenge
    
        at
            <a href="http://www.linkedin.com/companies/materials-research-society" >Materials Research Society</a>

                            </li>
                            <li>




            
      Seed Investor
    
 at ContraFect

                            </li>
                            <li>




            
      Advisory Board
    
 at Arroyo Paseo Charter High School

                            </li>
                            <li>




            
      Advisor &amp; Judge
    
 at BioEASI

                            </li>
                            <li>




            
      Advisory Board Member for Chemistry Department
    
        at
            <a href="http://www.linkedin.com/companies/imperial-college-london" >Imperial College London</a>

                            </li>
                            <li>




            
      Advisory Board Member
    
 at Cambridge Science Festival

                            </li>
                            <li>




            
      Xconomist
    
        at
            <a href="http://www.linkedin.com/companies/xconomy" >xConomy</a>

                            </li>
                            <li>




            
      Judge WSJ Innovation Awards
    
 at Wall Street Jorurnal Innovation Awards

                            </li>
                            <li>




            
      Inspiration and Executive Director
    
 at SAN DIEGO SCIENCE FESTIVAL

                            </li>
                            <li>




            
      Advisor
    
 at www.MySDScience.com

                            </li>
                            <li>




            
      Seed Investor
    
 at Siluria Technologies, Inc.

                            </li>
                            <li>




            
      EIR
    
 at CONNECT

                            </li>
                            <li>




            
      Tutor
    
 at St. Lukes Refugee Network

                            </li>
                            <li>




            
      Mentor - Burmese Refugees
    
        at
            <a href="http://www.linkedin.com/companies/jewish-family-services" >Jewish Family Services</a>

                            </li>
                            <li>




            
      Kayak Trainer for Disabled Vets
    
 at Team River Running

                            </li>
                            <li>




            
      Advisor &amp; Seed Investor
    
 at ekoVenture

                            </li>
                            <li>




            
      Seed Investor
    
 at Sapphire Energy

                            </li>
                            <li>




            
      Seed Investor
    
 at Siluria

                            </li>
                            <li>




            
      Co-founder
    
        at
            <a href="http://www.linkedin.com/companies/genocea-biosciences" >Genocea Biosciences</a>

                            </li>
                            <li>




            
      Partner
    
 at Bock Family Ventures

                            </li>
                            <li>




            
      Director
    
        at
            <a href="http://www.linkedin.com/companies/fei-company" >FEI Company</a>

                            </li>
                            <li>




            
      Seed Investor
    
 at Cambrios

                            </li>
                            <li>




            
      Founder and Initial Executive Chairman and CEO
    
 at Nanosys Inc.

                            </li>
                            <li>




            
      Limited Partner
    
        at
            <a href="http://www.linkedin.com/companies/venrock" >Venrock Associates</a>

                            </li>
                            <li>




            
      Seed Investor
    
        at
            <a href="http://www.linkedin.com/companies/acceleron-pharma" >Acceleron Pharma</a>

                            </li>
                            <li>




            
      Special Limited Partner
    
 at Lux Capital

                            </li>
                            <li>




            
      Scientific Advisory Board
    
 at Protia

                            </li>
                            <li>




            
      Memberof Advisory Board
    
 at PECSEA

                            </li>
                            <li>




            
      Seed Investor
    
        at
            <a href="http://www.linkedin.com/companies/sirtris-pharmaceuticals" >Sirtris Pharmaceuticals</a>

                            </li>
                            <li>




            
      Seed Investor
    
        at
            <a href="http://www.linkedin.com/companies/plexxikon-inc%2E" >Plexxikon</a>

                            </li>
                            <li>




            
      Co-founder
    
        at
            <a href="http://www.linkedin.com/companies/fast-track" >Fast Track Systems</a>

                            </li>
                            <li>




            
      Founder
    
        at
            <a href="http://www.linkedin.com/companies/illumina" >Illumina Inc.</a>

                            </li>
                            <li>




            
      General Partner
    
 at CW Group

                            </li>
                            <li>




            
      Co-founder
    
        at
            <a href="http://www.linkedin.com/companies/conforma-therapeutics" >Conforma Therapeutics</a>

                            </li>
                            <li>




            
      Seed Investor
    
        at
            <a href="http://www.linkedin.com/companies/surface-logix" >Surface Logix</a>

                            </li>
                            <li>




            
      Co-founder
    
 at Community Cousins

                            </li>
                            <li>




            
      Seed Investor
    
        at
            <a href="http://www.linkedin.com/companies/spectral-genomics" >Spectral Genomics</a>

                            </li>
                            <li>




            
      Founder and Initial CEO
    
        at
            <a href="http://www.linkedin.com/companies/argonaut-technologies" >Argonaut ~Technologies</a>

                            </li>
                            <li>




            
      Co-founder
    
 at Aurorra Biosciences

                            </li>
                            <li>




            
      Founder and Initial CEO
    
 at IDUN Pharmaceuticals

                            </li>
                            <li>




            
      Founder and Initial CEO
    
        at
            <a href="http://www.linkedin.com/companies/caliper-life-sciences" >Caliper Life Sciences</a>

                            </li>
                            <li>




            
      Founder
    
        at
            <a href="http://www.linkedin.com/companies/onyx-pharmaceuticals" >Onyx Pharmaceuticals</a>

                            </li>
                            <li>




            
      Seed Investor
    
 at River Medical

                            </li>
                            <li>




            
      Seed Investor
    
 at Sequana Therapeutics

                            </li>
                            <li>




            
      Seed Investor
    
 at Microcide Pharmaceuticals

                            </li>
                            <li>




            
      Founder and Initial CEO
    
        at
            <a href="http://www.linkedin.com/companies/pharmacopeia" >Pharmacopeia</a>

                            </li>
                            <li>




            
      Founder
    
 at ARIAD Pharmaceticals

                            </li>
                            <li>




            
      Founder and Initial CEO
    
        at
            <a href="http://www.linkedin.com/companies/neurocrine-biosciences" >Neurocrine Biosciences</a>

                            </li>
                            <li>




            
      Founder and Initial CEO
    
        at
            <a href="http://www.linkedin.com/companies/metra" >Metra Biosystems</a>

                            </li>
                            <li>




            
      Co-founder
    
        at
            <a href="http://www.linkedin.com/companies/vertex-pharmaceuticals" >Vertex Pharmaceuticals</a>

                            </li>
                            <li>




            
      Co-founder
    
        at
            <a href="http://www.linkedin.com/companies/genpharm-inc%2E" >GenPharm International</a>

                            </li>
                            <li>




            
      First Round Investor
    
        at
            <a href="http://www.linkedin.com/companies/viagen" >Viagene</a>

                            </li>
                            <li>




            
      First Round Investor
    
 at Gensia Pharmaceuticals

                            </li>
                            <li>




            
      Second Round Investor
    
        at
            <a href="http://www.linkedin.com/companies/idec" >IDEC Pharmaceuticals</a>

                            </li>
                            <li>




            
      First Round Investor
    
 at Biosym Technologies

                            </li>
                            <li>




            
      First Round Investor
    
 at Cytotech

                            </li>
                            <li>




            
      Co-founder
    
 at Athena Neurosciences

                            </li>
                            <li>




            
      Husband
    
 at The Bock Family

                            </li>
                            <li>




            
      Second Round Investor
    
 at GenProbe

                            </li>
                    </ul>
                    <p class="seeall showhide-link"><a href="#" id="morecurr-hide">see less...</a></p>
                  </div>
                      <p class="seeall showhide-link"><a href="#" id="morecurr-show">59 more...</a></p>
              </dd>
              <dt>Past</dt>
              <dd>
                <ul>
                        <li>




            
      General Partner
    
        at
            <a href="http://www.linkedin.com/companies/avalon-ventures" >Avalon Ventures</a>

                        </li>
                        <li>




            
      Associate
    
 at Fairfield Ventures

                        </li>
                        <li>




            
      Summer Intern
    
 at Burr, Egan and Deleage

                        </li>
                </ul>
                  <div class="showhide-block" id="morepast">
                    <ul>
                            <li>




            
      Research Associate
    
        at
            <a href="http://www.linkedin.com/companies/genentech" >Genentech, Inc.</a>

                            </li>
                            <li>




            
      Student
    
        at
            <a href="http://www.linkedin.com/companies/bowdoin-college" >Bowdoin College</a>

                            </li>
                    </ul>
                    <p class="seeall showhide-link"><a href="#" id="morepast-hide">see less...</a></p>
                  </div>
                      <p class="seeall showhide-link"><a href="#" id="morepast-show">2 more...</a></p>
              </dd>
              <dt>Education</dt>
              <dd>
                <ul>
                      <li>
                        
           University of California, Los Angeles - The Anderson School of Management
      
                      </li>
                      <li>
                        
           Horace Greeley High School
      
                      </li>
                      <li>
                        
           Bowdoin College
      
                      </li>
                </ul>
                  <div class="showhide-block" id="moreedu">
                    <ul>
                    </ul>
                    <p class="seeall showhide-link"><a href="#" id="moreedu-hide">see less...</a></p>
                  </div>
              </dd>
              <dt class="recommended">Recommended</dt>
              <dd class="recommended">
<img src="http://static01.linkedin.com/img/icon/endorse/icon_endorse_3_35x24.gif" width="35" height="24" alt="Larry has 26 recommendations" title="Larry has 26 recommendations" />                <strong class="recommendation-count r3">26</strong> people have recommended Larry </dd>
              <dt class="connections">Connections</dt>
              <dd class="connections">
                <img src="http://static02.linkedin.com/img/icon/conx/icon_conx_16_24x24.gif" width="24" height="24" alt="" />
                <strong class="connection-count">
                500+
                </strong> connections
              </dd>

              <dt>Industry</dt>
              <dd>
                Nanotechnology
              </dd>
            
              <dt>Websites</dt>
              <dd>
                <ul>
                    <li>
<a href="http://www.youtube.com/watch?v=lF5B-539v-Q" rel="nofollow" class="url" target="_blank">UC Berkeley Commencement Addre</a>                    </li>
                    <li>
<a href="http://www.luxcapital.com/team_bock.php" rel="nofollow" class="url" target="_blank">Lux Capital</a>                    </li>
                    <li>
<a href="http://bowdoin.facebook.com/profile.php?id=721209637" rel="nofollow" class="url" target="_blank">FaceBook</a>                    </li>
                </ul>
              </dd>
          </dl>
        </div>
        <hr />
          <div id="summary">
            <h2>Larry Bock&#8217;s Summary</h2>
              <p class="summary">
                Serial entrepreneur and seed stage high technology and life sciencesventure capitalist<br>
<br>
Founded, co-founded or provided early stage financing to 40 companies that have achieved a cumulative market capitalization of over $40 Billion.<br>
<br>
Interested in American competitiveness and innovation and science education<br>
<br>
Interested in assisting refugee families achieve the American Dream.
              </p>
              <h3>Larry Bock&#8217;s Specialties:</h3>
              <p class="skills">
                de novo start-ups, entrepreneurship, biotechnology, nanotechnology, smart materials, renewable energy, biofuels, nanotechnology, technology licensing and talent recruitment, strategic partnerships, venture capital, seed capital, innovation, science education, science festivals, San Diego
              </p>
          </div>
          <hr />
          <div id="experience">
            <h2>Larry Bock&#8217;s Experience</h2>
            <ul class="vcalendar">



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Executive Director
    
      </h3>
      <h4 class="org summary">USA Science Festival</h4>
  <p class="organization-details">(Philanthropy industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2009-09-01">September 2009</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P3M">(3 months)</abbr>
  </p>
    <p class="description">The non-profit USA Science Festival&#x2018;s mission is to produce the most compelling, exciting, educational and entertaining science gathering in the United States. The Festival will unite our country showcasing the Science &amp; Innovation that makes the United States unique. Join the excitement! Join our Group!! Pass he Word!!!<br>
<br>
The Inaugural USA Science Festival will be the country&#x2019;s first national science festival and will be themed: <br>
<br>
&#x201c;The Science of US&#x201d;<br>
<br>
The Festival will celebrate science in general but will have special programs in areas such as clean technology, alternative energy, green chemistry, bio-mimicry, sustainability, ecology and conservation. The Festival&#x2019;s participants will include the nation&#x2019;s leading high technology, life sciences and clean technology companies, universities, colleges and research institutions, government agencies and federal laboratories, professional science societies and industry associations, informal science outreach organizations and potentially you. Our goal is to have one million people celebrating science on the Washington, D.C. Mall. The Festival is scheduled for the Fall of 2010.<br>
<br>
The USA Science Festival is modeled after the very popular and successful science festivals that take place internationally in the United Kingdom, Germany, Italy, India, Japan and Australia. These festivals are typically seven to fourteen day events, draw between 50,000-1,000,000 people and celebrate all aspects of science through inspiring lectures, hands-on activities and exhibits, contests, theatre, comedy, poetry, art and music &#x2013; all celebrating science. <br>
<br>
The Festival is being organized by Larry Bock, the creator of the Inaugural San Diego Science Festival (SM) which drew 200,000 people to over 500 free activities in the Spring of 2009.<br>
<br>
We will shortly be launching our website at: usasciencefestival.org<br>
<br>
Email us if you would like to learn about getting involved.<br>
<br>
Larry Bock<br>
biobock@mac.com</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Judge
    
      </h3>
      <h4 class="org summary">UC San Diego Entrepreneur Challenge</h4>
  <p class="organization-details">(Venture Capital &amp; Private Equity industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2009-06-01">June 2009</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P6M">(6 months)</abbr>
  </p>
    <p class="description"></p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Judge
    
      </h3>
      <h4 class="org summary">UC San Diego Entrepreneur Challenge</h4>
  <p class="organization-details">(Venture Capital &amp; Private Equity industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2009-06-01">June 2009</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P6M">(6 months)</abbr>
  </p>
    <p class="description"></p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Judge- Entrepreneurship Challenge
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/materials-research-society?trk=ppro_cprof&amp;lnk=vw_cprofile" >Materials Research Society</a></h4>
  <p class="organization-details">(Non-Profit; 11-50 employees; Non-Profit Organization Management industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2008">2008</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P1Y">(1 year )</abbr>
  </p>
    <p class="description">Judge material science based business plans for annual competition<br>
<br>
http://lucy.mrs.org/entrepreneur/index.html</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary">ContraFect</h4>
  <p class="organization-details">(Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2008-07-01">July 2008</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P1Y5M">(1 year 5 months)</abbr>
  </p>
    <p class="description">Infections in the hospital are the 8th leading cause of death in the United States. This occurs primarily because of drug-resistant and newly-emerging pathogens.  While bacteria and viruses are treated with antibiotics and antiviral drugs, they have a series of escape mechanisms that come from mutation.  Ultimately, all antibiotics become inactive as drug-resistant bacteria arise.  In addition, viruses become resistant by mutation and the survival of strains that avoid immune attack.  ContraFect Corporation has been formed to address these life threatening infections.  Combination  therapy will be used to block and disarm virulence factors of  bacteria and viruses, rendering them vulnerable to the natural immune balance of the body.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Advisory Board
    
      </h3>
      <h4 class="org summary">Arroyo Paseo Charter High School</h4>
  <p class="organization-details">(Philanthropy industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2008-07-01">July 2008</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P1Y5M">(1 year 5 months)</abbr>
  </p>
    <p class="description">Arroyo Paseo Charter High School is a new start-up charter school based in an urban community of San Diego. The school will enroll 110 students in 2007/08 and have a future maximum enrollment of 250 9th to 12th grade students. The mission of APCHS is to prepare, support and motivate all students, especially students from the diverse urban communities of San Diego, to pursue careers at all levels of science, technology, engineering, and mathematics by providing a rigorous, standards-based, educational program designed to support the academic success of all learners.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Advisor &amp; Judge
    
      </h3>
      <h4 class="org summary">BioEASI</h4>
  <p class="organization-details">(Philanthropy industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2008-06-01">June 2008</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P1Y6M">(1 year 6 months)</abbr>
  </p>
    <p class="description">The gap between the increasingly rapid advances in scientific research and the stationary state of the public&#x2019;s knowledge in the basic sciences is ever widening. It is becoming more difficult for scientists to convey the significance of their research to the public. Public interest is becoming crucial to deciding the fate of that research. There is a desperate need for new ways to re-ignite the public&#x2019;s interest and support.<br>
<br>
Art is valued universally for its capacity to capture ideas and evoke feelings from people in a way that words cannot. In this faculty, art presents itself as a final resort for making even the most complex issues of science accessible to anyone and everyone. Therefore, the mission of BioEASI is to transform the fruits of scientific research into works of art meant to inspire public interest in science and to direct the funds from art sales into public education and research training.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Advisory Board Member for Chemistry Department
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/imperial-college-london?trk=ppro_cprof&amp;lnk=vw_cprofile" >Imperial College London</a></h4>
  <p class="organization-details">(Educational Institution; 5001-10,000 employees; Research industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2008-06-01">June 2008</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P1Y6M">(1 year 6 months)</abbr>
  </p>
    <p class="description">http://www3.imperial.ac.uk/chemistry/people/externaladvisoryboard</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Advisory Board Member
    
      </h3>
      <h4 class="org summary">Cambridge Science Festival</h4>
  <p class="organization-details">(Non-Profit; 1-10 employees; Philanthropy industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2008">2008</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P1Y">(1 year )</abbr>
  </p>
    <p class="description">National Science Festival in Boston, MA<br>
<br>
http://cambridgesciencefestival.org/2007/index.php</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Xconomist
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/xconomy?trk=ppro_cprof&amp;lnk=vw_cprofile" >xConomy</a></h4>
  <p class="organization-details">(Privately Held; 1-10 employees; Internet industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2008-06-01">June 2008</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P1Y6M">(1 year 6 months)</abbr>
  </p>
    <p class="description">Xconomy is dedicated to providing business and technology leaders with timely, insightful, close-to-the-scene information about the local personalities, companies, and technological trends that best exemplify today&#x2019;s high-tech economy.<br>
<br>
Xconomy's goalis to become the authoritative voice on the exponential economy, the realm of business and innovation characterized by exponential technological growth and responsible for an increasing share of productivity and overall economic growth.<br>
<br>
Xconomy plans to deliver this valuable content through a unique global network of localized blogs, events, conferences, and other initiatives designed to better connect people and ideas.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Judge WSJ Innovation Awards
    
      </h3>
      <h4 class="org summary">Wall Street Jorurnal Innovation Awards</h4>
  <p class="organization-details">(Venture Capital &amp; Private Equity industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2008-03-01">March 2008</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P1Y9M">(1 year 9 months)</abbr>
  </p>
    <p class="description">Judge at the Wall Street Journal Innovation Awards.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Inspiration and Executive Director
    
      </h3>
      <h4 class="org summary">SAN DIEGO SCIENCE FESTIVAL</h4>
  <p class="organization-details">(Philanthropy industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2008-01-01">January 2008</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P1Y11M">(1 year 11 months)</abbr>
  </p>
    <p class="description">Join our group:  http://www.linkedin.com/e/gis/90792/00B1D174A4C3<br>
<br>
The non-profit San Diego Science Festival&#x2019;s mission is to produce and present the most compelling, exciting, educational and entertaining science gathering on the West Coast, The Inaugural San Diego Science Festival will unite our community to showcase the Science &amp; Innovation that makes Southern California unique! Join us for the first full-scale celebration of Science the West Coast has ever seen!  The month-long event celebrates the Science and Innovation all around us with events, lectures, and activities countywide to engage all audiences from students, to teachers, to parents, to science professionals, or anyone that is just curious.  If you want to be part of the excitement, join our Group!!</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Advisor
    
      </h3>
      <h4 class="org summary">www.MySDScience.com</h4>
  <p class="organization-details">(Civic &amp; Social Organization industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2008-01-01">January 2008</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P1Y11M">(1 year 11 months)</abbr>
  </p>
    <p class="description">Working with a team of UCSD/Salk graduate students  and post docs on the creation of a Social Network for Scientists</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary">Siluria Technologies, Inc.</h4>
  <p class="organization-details">(Privately Held; 1-10 employees; Nanotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2007">2007</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P2Y">(2 years )</abbr>
  </p>
    <p class="description">Provided seed capital for the start of Siluria</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      EIR
    
      </h3>
      <h4 class="org summary">CONNECT</h4>
  <p class="organization-details">(Venture Capital &amp; Private Equity industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2007-09-01">September 2007</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P2Y3M">(2 years 3 months)</abbr>
  </p>
    <p class="description">Assist start-up entrepreneurs craft their message<br>
<br>
http://www.connect.org/programs/springboard/entrepreneurs.htm</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Tutor
    
      </h3>
      <h4 class="org summary">St. Lukes Refugee Network</h4>
  <p class="organization-details">(Non-Profit; 11-50 employees; Philanthropy industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2007">2007</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P2Y">(2 years )</abbr>
  </p>
    <p class="description">Tutor Sudanese refugee children in math and science.<br>
<br>
The St. Luke's Refugee Network supports families during their years of adjustment to American life by providing help in:<br>
 <br>
Enrolling children at school Social Security registration Welfare/benefits registration,<br>
Translation for medical visits, official interviews<br>
Registering children at school,<br>
Assistance in obtaining apartments and obtaining employment.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Mentor - Burmese Refugees
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/jewish-family-services?trk=ppro_cprof&amp;lnk=vw_cprofile" >Jewish Family Services</a></h4>
  <p class="organization-details">(Non-Profit; 11-50 employees; Philanthropy industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2007">2007</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P2Y">(2 years )</abbr>
  </p>
    <p class="description">This is a group of Mentors in the Refugee Resettlement Friendly Match -- a program of Jewish Family Services of San Diego, to help Burmese Refugees integrate into the United States.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Kayak Trainer for Disabled Vets
    
      </h3>
      <h4 class="org summary">Team River Running</h4>
  <p class="organization-details">(Non-Profit; 1-10 employees; Philanthropy industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2007">2007</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P2Y">(2 years )</abbr>
  </p>
    <p class="description">Train disabled veterans to whitewater kayak.<br>
<br>
Team River Running's  goal is to help  veterans recuperating at Walter Reed Army Medical Center (WRAMC) and other military and veterans hospitals around the country find health, healing, and new challenges through whitewater boating. While the focus of Team River Runner's work is on soldiers, TRR also provides water-based recreational opportunities for their family members as well.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Advisor &amp; Seed Investor
    
      </h3>
      <h4 class="org summary">ekoVenture</h4>
  <p class="organization-details">(Internet industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2007">2007</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P2Y">(2 years )</abbr>
  </p>
    <p class="description">Coming in early 2008, ekoVenture is an online adventure travel community bringing together all global tour operators and adventure travelers into one interactive place. ekoVenture allows the adventurer to find all adventure tours that meet their requirements, connect with others like them though a set of interactive experiences, and then book the travel directly on ekoVenture.com. <br>
<br>
Core to the ekoVenture brand is the promise to allocate 10% of profits towards environmental sustainability and protection.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary">Sapphire Energy</h4>
  <p class="organization-details">(Oil &amp; Energy industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2007-06-01">June 2007</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P2Y6M">(2 years 6 months)</abbr>
  </p>
    <p class="description">Sapphire&#x2019;s goal is to be the world&#x2019;s leading producer of renewable petrochemical products. With Pyle leading the group, the team has built a revolutionary molecular platform that converts sunlight and CO2 into renewable, carbon-neutral alternatives to conventional fossil fuels without the numerous downsides of current biofuel efforts.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary">Siluria</h4>
  <p class="organization-details">(Electrical/Electronic Manufacturing industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2007-01-01">January 2007</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P2Y11M">(2 years 11 months)</abbr>
  </p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Co-founder
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/genocea-biosciences?trk=ppro_cprof&amp;lnk=vw_cprofile" >Genocea Biosciences</a></h4>
  <p class="organization-details">(Privately Held; 11-50 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2006">2006</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P3Y">(3 years )</abbr>
  </p>
    <p class="description">Co-Founder of this company<br>
<br>
http://www.genocea.com/<br>
<br>
Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. When they work, vaccines are one of the most effective ways of preventing and treating disease. Unfortunately, many research and clinical vaccine programs are hit-and-miss because there is currently no way to screen all possible antigens or predict which ones will work. To remove the guesswork, we need the ability to mimic the human immune system in vitro so one can identify which antigenic epitopes will elicit a competent immune response.  <br>
<br>
Genocea can rapidly identify antigens that result in the in vivo stimulation of protective CD8+ and CD4+ T-cells, targets that can be immediately incorporated into existing antigen delivery systems to produce multivalent vaccine formulations that have the highest probability of generating protective cell-mediated immunity.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Partner
    
      </h3>
      <h4 class="org summary">Bock Family Ventures</h4>
  <p class="organization-details">(Venture Capital &amp; Private Equity industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2006">2006</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P3Y">(3 years )</abbr>
  </p>
    <p class="description">Seed stage investor in Acceleron Pharma (Private &#x2013; metabolic and musculoskeletal diseases), Cambrios (Priviae &#x2013; high performance electronic materials), Magen Biosciences (Private &#x2013; dermatology and skin care),  Plexikon Pharmaceuticals (Private &#x2013; scaffold based drug design) Poland Partners (Private - a $62.5M  venture capital fund investing in Central Europe), Saphire Energy  (Private &#x2013; biofuels), and Siluria Technologies Inc. (Private - biologyy directed electronic assembly) and Sirtris Pharmaceticals (NASDAQ: SIRT &#x2013; gene regulation).</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Director
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/fei-company?trk=ppro_cprof&amp;lnk=vw_cprofile" >FEI Company</a></h4>
  <p class="organization-details">(Public Company; 1001-5000 employees; FEIC; Nanotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2004-01-01">January 2004</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P5Y11M">(5 years 11 months)</abbr>
  </p>
    <p class="description">Board Member and Member of the Compensation Committee, Strategy Committees<br>
<br>
http://www.fei.com<br>
<br>
From the world's first DualBeam&#x2122; system, to market-leading scanning electron microscopes, to the world's most powerful, commercially-available transmission electron microscope, FEI's Tools for Nanotech are enabling researchers, scientists, and industrial pioneers to see, analyze, and manipulate two- and three-dimensional nanoscale structures. Our market-leading instruments, which include scanning electron microscopes, transmission electron microscopes, Dualbeam&#x2122; systems, and focused ion beam tools, push the boundaries of discovery and exploration, facilitating breakthroughs in pharmacology, biotechnology, forensics, pathology, materials science, semiconductor manufacturing and data storage.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary">Cambrios</h4>
  <p class="organization-details">(Privately Held; 11-50 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2004">2004</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P5Y">(5 years )</abbr>
  </p>
    <p class="description">Provided seed capital for the start of Cambrios<br>
<br>
http://www.cambrios.com/<br>
<br>
Cambrios is currently focused on the development of electronic materials for the display industry.  Cambrios proprietary nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components at lower manufacturing cost.  The company&#x2019;s first product, a directly patternable, wet-processable transparent conductive film, is poised to replace the industry standard sputtered indium tin oxide (ITO).  Subsequent products will leverage this technology to produce other functional films for display and thin films applications.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Founder and Initial Executive Chairman and CEO
    
      </h3>
      <h4 class="org summary">Nanosys Inc.</h4>
  <p class="organization-details">(Privately Held; 51-200 employees; Nanotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2003">2003</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P6Y">(6 years )</abbr>
  </p>
    <p class="description">Original Founder and Initial CEO and Executive Chairman of this company<br>
<br>
http://www.nanosysinc.com<br>
<br>
Founded in 2001 by an experienced business team and world-renowned nanotechnology leaders, Nanosys is an industry-leading nanotechnology company developing, manufacturing and selling products based on a technology platform of high performance inorganic nanostructures. Nanosys' technology is covered by a portfolio of over 500 patents and patent applications that is currently being applied to opportunities in multiple industries including energy, electronics, optoelectronics, life science, and defense. Current application areas of Nanosys technology include flat-panel displays, non-volatile memory, fuel cells, solid-state lighting, chemical analysis chips and medical devices.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Limited Partner
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/venrock?trk=ppro_cprof&amp;lnk=vw_cprofile" >Venrock Associates</a></h4>
  <p class="organization-details">(Partnership; 11-50 employees; Venture Capital &amp; Private Equity industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2003">2003</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P6Y">(6 years )</abbr>
  </p>
    <p class="description">Limited Partner  in Venrock's Entrepreneurs side fund<br>
<br>
http://www.venrock.com<br>
<br>
Venrock is a premier venture capital firm with offices in Menlo Park, New York, Cambridge, MA, and Israel.  Originally established as the venture capital arm of the Rockefeller family, Venrock continues a seven-decade tradition of partnering with entrepreneurs to establish successful, enduring companies.  Having invested $1.9 billion in 405 companies resulting in 124 IPOs and 114 M&amp;A exits over the past 38 years, Venrock's investment returns place it among the top tier venture capital firms that have achieved consistently superior performance.  With a primary focus on technology, healthcare, and energy, portfolio companies have included Apple Computer, Centocor, Check Point Software, DoubleClick, Gilead Sciences, Idec Pharmaceuticals, Illumina, Intel, Millennium Pharmaceuticals, Sirna Therapeutics, and StrataCom.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/acceleron-pharma?trk=ppro_cprof&amp;lnk=vw_cprofile" >Acceleron Pharma</a></h4>
  <p class="organization-details">(Privately Held; 11-50 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2003">2003</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P6Y">(6 years )</abbr>
  </p>
    <p class="description">Provided seed capital for launch of Acceleron Pharma<br>
<br>
http://www.acceleronpharma.com<br>
<br>
Since its initial financing in 2004, Acceleron&#x2019;s goal has been to develop innovative therapies. Acceleron has built in-house drug development capabilities, allowing it to focus its creativity and innovation on the biology of the GDF protein family, while streamlining the development of novel therapies.<br>
<br>
This strategy has already yielded a rich pipeline of compounds that have the potential to be therapeutic breakthroughs for a number of devastating diseases. Acceleron's approach has opened a completely new area of GDF-targeted therapies that can modulate the growth and repair of a variety of tissue systems, offering new hope and benefits to patients.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Special Limited Partner
    
      </h3>
      <h4 class="org summary">Lux Capital</h4>
  <p class="organization-details">(Partnership; 11-50 employees; Nanotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2003">2003</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P6Y">(6 years )</abbr>
  </p>
    <p class="description">http://www.luxcapital.com/<br>
<br>
Lux Capital Management is a research-driven investment firm focused on de novo, seed and early stage investments in the physical and life sciences. Lux takes an active role in helping management teams build successful businesses in high growth sectors. Our investment team has built over 20 companies from scratch.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Scientific Advisory Board
    
      </h3>
      <h4 class="org summary">Protia</h4>
  <p class="organization-details">(Privately Held; 1-10 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2003">2003</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P6Y">(6 years )</abbr>
  </p>
    <p class="description">Protia utilizes a new discovery with which we chemically modify existing,  pharmaceuticals to create new, patentable derivatives of those pharmaceuticals.  Protia's  technology is the only way in which the size of drug molecules can be made smaller.    The properties of Protia-modified drugs will change the beneficial bioactivity of these drugs in subtle ways, but in ways that should not change their toxicity or bioavailability properties.  Furthermore, the manufacture of Protia-modified drugs will benefit by utilizing existing plants and production methods.  The modest increase in manufacturing cost will be far offset by the ability to obtain new patents.  Protia has already obtained an Allowance from the USPTO on our first patent application.  Subsequently, Protia has filed pending patent applications on the 240 small molecule drugs predicted each to earn annually more than $500MM.  In the best case scenario, that makes the potential market for Protia's IP exceed $120B annually.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Memberof Advisory Board
    
      </h3>
      <h4 class="org summary">PECSEA</h4>
  <p class="organization-details">(Government Agency; 11-50 employees; Government Administration industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2003">2003</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P6Y">(6 years )</abbr>
  </p>
    <p class="description">Fp\ocused on nanotechnology export administration<br>
<br>
http://www.ita.doc.gov/td/pec/index.html<br>
<br>
PECSEA- President's Export Council Subcommittee on Export Administration. A subcommittee of the President's Export Council. The PECSEA is an advisory committee whose members are appointed by the Secretary of Commerce to advise the U.S. Government on matters and issues pertinent to implementation of the provisions of the Export Administration Act (EAA) and the Export Administration Regulations (EAR). The PECSEA is composed primarily of representatives from the private sector.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/sirtris-pharmaceuticals?trk=ppro_cprof&amp;lnk=vw_cprofile" >Sirtris Pharmaceuticals</a></h4>
  <p class="organization-details">(Public Company; 11-50 employees; SIRT; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2002">2002</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P7Y">(7 years )</abbr>
  </p>
    <p class="description">Provided seed capital for the start of Sirtris Pharmaceuticals<br>
<br>
Sirtris was bought by Glaxo Wellcome for $750M<br>
<br>
http://www.sirtrispharma.com/<br>
<br>
Sirtris Pharmaceuticals&#x2122; (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company's headquarters are in Cambridge, Massachusetts</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/plexxikon-inc%2E?trk=ppro_cprof&amp;lnk=vw_cprofile" >Plexxikon</a></h4>
  <p class="organization-details">(Privately Held; 11-50 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2000">2000</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P9Y">(9 years )</abbr>
  </p>
    <p class="description">Provided seed capital for the start of Plexxikon<br>
<br>
http://www.plexxikon.com<br>
<br>
Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including metabolic disease, oncology, inflammation, CNS and cardiovascular disease.<br>
<br>
With its Scaffold-Based Drug Discovery Platform&#x2122;, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. .<br>
<br>
Plexxikon&#x2019;s business strategy is to generate competitively differentiated drug candidates across multiple therapeutic areas, then partner at the IND or early clinical stage for further co-development and commercialization.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Co-founder
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/fast-track?trk=ppro_cprof&amp;lnk=vw_cprofile" >Fast Track Systems</a></h4>
  <p class="organization-details">(Privately Held; Sports industry)</p>
  <p class="period">
        <abbr class="dtstart" title="2000">2000</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P9Y">(9 years )</abbr>
  </p>
    <p class="description">Co-founded this company focused on accelerating clinical development  Fast Track merged with Medidata Solutions (NASDAQ: MDSO)<br>
<br>
http://www.fast-track.com<br>
	<br>
As a world-class provider of clinical trial software and professional services to pharmaceutical and biotechnology companies, Fast Track Systems, Inc., provides a true competitive edge in the clinical development process through authoring protocols; planning, negotiating, or managing trial budgets; seeking to drastically reduce trial cycle times; and/or needing to maintain strict fiscal responsibility.<br>
<br>
Fast Track&#x2019;s global cost and procedure benchmarking databases; drawn from over 240,000 negotiated investigator agreements, 25,000 finalized protocols and 3,000 CRO contracts, have been the most relevant industry resource for over 14 years. Over 50 of the top pharmaceutical companies rely on our products to enable clinical researchers, finance staff and medical management to efficiently collaborate in making informed decisions that influence the execution of the final clinical plan.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Founder
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/illumina?trk=ppro_cprof&amp;lnk=vw_cprofile" >Illumina Inc.</a></h4>
  <p class="organization-details">(Public Company; 201-500 employees; ILMN; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1999">1999</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P10Y">(10 years )</abbr>
  </p>
    <p class="description">Original Founder of this company<br>
<br>
http://www.illumina.com<br>
<br>
Illumina&#x2019;s mission is to develop next-generation tools for the large-scale analysis of genetic variation and function, the results of which will pave the way for personalized medicine, a key goal of genomics and proteomics.<br>
<br>
Illumina's goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service.  Illumina&#x2019;s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      General Partner
    
      </h3>
      <h4 class="org summary">CW Group</h4>
  <p class="organization-details">(Partnership; 1-10 employees; Venture Capital &amp; Private Equity industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1999">1999</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P10Y">(10 years )</abbr>
  </p>
    <p class="description">Seed and early stage healthcare venture capital fund<br>
<br>
http://www.cwventures.com/<br>
<br>
CW Group, a leading manager of medical venture capital funds focused on seed and early stage healthcare investing, welcomes you to our Web Site.<br>
<br>
CW Group invests in seed and early stage healthcare companies which have the potential to grow rapidly into substantial enterprises. CW Group invests primarily in companies it co-founds with leading scientists and entrepreneurs in the areas of biotechnology, including pharmaceuticals, genomics and diagnostics; medical devices and instrumentation; healthcare services and medical information systems.<br>
<br>
CW Group has managed seven medical venture capital funds, and since 1982 has invested in the early financing of over 70 companies. CW Group's limited partners include major corporations, pension funds, endowment funds, financial institutions, and private investors.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Co-founder
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/conforma-therapeutics?trk=ppro_cprof&amp;lnk=vw_cprofile" >Conforma Therapeutics</a></h4>
  <p class="organization-details">(Public Company; 51-200 employees; PFE; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1998">1998</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P11Y">(11 years )</abbr>
  </p>
    <p class="description">Co-founder of this company that was acquired by Pfizer for $250 million.<br>
<br>
Conforma Therapeutics (acquired by Pfizer) , a San Diego-based biopharmaceutical company, was focused on the design and development of novel drugs for the treatment of cancer. Conforma&#x2019;s internal discovery efforts have been focused on drugs that target the cellular HSP90 family of molecular &quot;chaperones&quot; that control protein <br>
shape or conformation, including that of key signaling molecules involved in the growth and survival of tumor cells. HSP90-directed drugs selectively induce the degradation of these cancer-promoting proteins, <br>
leading to tumor cell death. Conforma is conducting Phase I clinical trials with its lead HSP90 product, CNF1010, for the treatment of cancer and plans to initiate clinical testing of its second, orally administered HSP90 product, CNF2024, in the third quarter of 2005.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/surface-logix?trk=ppro_cprof&amp;lnk=vw_cprofile" >Surface Logix</a></h4>
  <p class="organization-details">(Privately Held; 11-50 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1998">1998</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P11Y">(11 years )</abbr>
  </p>
    <p class="description">Provided seed capital for the start of Surface Logix<br>
<br>
http://www.surfacelogix.com	<br>
 <br>
Surface Logix Inc. uses its expertise in biophysical chemistry to create new small molecule drugs that are optimized to meet the challenges of human physiology. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Co-founder
    
      </h3>
      <h4 class="org summary">Community Cousins</h4>
  <p class="organization-details">(Non-Profit; 1-10 employees; Civic &amp; Social Organization industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1995">1995</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P14Y">(14 years )</abbr>
  </p>
    <p class="description">Founded with wife, Community Cousins, a non-profit foundation focused on breaking down racial barriers, that was selected by former Vice President Al Gore as one of ten outstanding grass root efforts nationally.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/spectral-genomics?trk=ppro_cprof&amp;lnk=vw_cprofile" >Spectral Genomics</a></h4>
  <p class="organization-details">(Nanotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1995">1995</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P14Y">(14 years )</abbr>
  </p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Founder and Initial CEO
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/argonaut-technologies?trk=ppro_cprof&amp;lnk=vw_cprofile" >Argonaut ~Technologies</a></h4>
  <p class="organization-details">(Public Company; 201-500 employees; BIOT; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1994">1994</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P15Y">(15 years )</abbr>
  </p>
    <p class="description">Original Founder and Initial CEO of this Argonaut that went public and subsequently merged with Biotage<br>
<br>
http://www.biotage.com<br>
<br>
Biotage AB is a global company providing innovative solutions, knowledge and experience in the areas of medicinal and analytical chemistry, process development and genetic analysis. The company&#x2019;s strengths include revolutionary high-quality technologies, a broad business base and a long-term view of the market. <br>
<br>
Biotage intends to continue expanding its business and product portfolio. The company aims to help its global customers meet the enormous pressures of time, cost and innovation. Its mission is to lead customers successfully into the next era of research, discovery and development with its solutions and services.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Co-founder
    
      </h3>
      <h4 class="org summary">Aurorra Biosciences</h4>
  <p class="organization-details">(Privately Held; 1001-5000 employees; VRTX; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1994">1994</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P15Y">(15 years )</abbr>
  </p>
    <p class="description">Co-founder of this company that went public and was subsequently  acquired by Vertex Pharmaceuticals for $700 million.<br>
<br>
http://www.vpharm.com/<br>
<br>
Aurora Biosciences Corporation (acquired by Vertex)  designs, develops and commercializes proprietary drug discovery systems, services and technologies to accelerate and enhance the discovery of new medicines. Aurora is developing a proprietary, ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation and informatics. Aurora believes its integrated platform will shorten the time required to identify high quality lead compounds and to optimize those compounds into drug development candidates.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Founder and Initial CEO
    
      </h3>
      <h4 class="org summary">IDUN Pharmaceuticals</h4>
  <p class="organization-details">(Privately Held; 201-500 employees; PFE; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1993">1993</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P16Y">(16 years )</abbr>
  </p>
    <p class="description">Original Founder and Initial CEO of this company that was acquired by Pfizer for $250 million<br>
<br>
Idun Pharmaceuticals, Inc. (acquired by Pfizer) was  a privately-held biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the areas of liver disease, inflammation, and cancer. Idun's lead product candidate, IDN-6556, is in clinical studies for both liver transplantation and in patients infected with Hepatitis C virus. The company has a number of product candidates in advanced preclinical development for inflammation and cancer. Idun has an extensive patent portfolio comprised of 145 issued patents worldwide. Idun's corporate headquarters and research and development facility was located in San Diego, California.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Founder and Initial CEO
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/caliper-life-sciences?trk=ppro_cprof&amp;lnk=vw_cprofile" >Caliper Life Sciences</a></h4>
  <p class="organization-details">(Public Company; 201-500 employees; CALP; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1992">1992</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P17Y">(17 years )</abbr>
  </p>
    <p class="description">Original Founder and Initial CEO of this company<br>
<br>
http://www.caliperls.com<br>
<br>
Caliper Life Sciences combines microfluidics, liquid handling and laboratory automation to deliver unique research tools for today&#x2019;s Drug Discovery and Development and Genomics and Proteomics laboratories. We manufacture and sell products such as the LabChip 3000 Drug Discovery system, Caliper Sciclone liquid handler, Staccato Assay Workstations, and the LabChip 90 Automated Electrophoresis system. Each of these products addresses critical applications within the life sciences industry; each of these applications is on the critical path to improving human health.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Founder
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/onyx-pharmaceuticals?trk=ppro_cprof&amp;lnk=vw_cprofile" >Onyx Pharmaceuticals</a></h4>
  <p class="organization-details">(Public Company; 501-1000 employees; ONXX; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1992">1992</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P17Y">(17 years )</abbr>
  </p>
    <p class="description">Co-founder and Initial investor in Onyx Pharmaceuticals<br>
<br>
http://www.onyx-pharm.com<br>
<br>
Onyx Pharmaceuticals is developing innovative small molecule cancer treatments based on a molecular understanding of cancer. Onyx lead product is Nexavar&#xae; (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). This product is being  marketed in collaboration with Bayer HealthCare Pharmaceuticals. <br>
<br>
Nexavar is approved in more than 60 countries for the treatment of patients with advanced kidney cancer. In addition, we were recently granted approval in a second indication, liver cancer, in the U.S. and E.U.  <br>
<br>
Onyx also have a second product in clinical testing, a small molecule cell cycle inhibitor that resulted from a collaboration with Pfizer, which is responsible for developing the drug.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary">River Medical</h4>
  <p class="organization-details">(Privately Held; 201-500 employees; AMI; Medical Devices industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1992">1992</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P17Y">(17 years )</abbr>
  </p>
    <p class="description">Seed Investor in River Medical which did an LBO of IVAC and was subsequently acquired by IMED to become Alaris Medical.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary">Sequana Therapeutics</h4>
  <p class="organization-details">(Public Company; 51-200 employees; sqna; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1992">1992</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P17Y">(17 years )</abbr>
  </p>
    <p class="description">Inital investor in Sequana Therapeutics<br>
<br>
Sequana Therapeutics was a leading genomics company that uses industrial-scale gene finding technologies and functional genomics to develop products aimed at diagnosing and treating common human diseases<br>
<br>
Arris Pharamceuticals acquired Sequana Therapeutics in 1997 to become Axys Pharmaceuticals. Axys went on to form Axys Advanced Technologies, which got bought by ChemRx, becoming ChemRx Advanced Technologies. Axys was bought by Celera Genomics and now operates as Celera.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Seed Investor
    
      </h3>
      <h4 class="org summary">Microcide Pharmaceuticals</h4>
  <p class="organization-details">(Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1992">1992</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P17Y">(17 years )</abbr>
  </p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Founder and Initial CEO
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/pharmacopeia?trk=ppro_cprof&amp;lnk=vw_cprofile" >Pharmacopeia</a></h4>
  <p class="organization-details">(Public Company; PCOP; Pharmaceuticals industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1991">1991</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P18Y">(18 years )</abbr>
  </p>
    <p class="description">Original Founder of this company<br>
<br>
Pharmacopeia merged with Ligand Pharmaceuticals.<br>
<br>
http://www.pharmacopeia.com<br>
<br>
Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or with partners including seven clinical compounds in Phase 2 or Phase 1 development addressing hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Organon, Schering-Plough, and Wyeth Pharmaceuticals.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Founder
    
      </h3>
      <h4 class="org summary">ARIAD Pharmaceticals</h4>
  <p class="organization-details">(Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1989">1989</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P20Y">(20 years )</abbr>
  </p>
    <p class="description">Original Founder of this company<br>
<br>
http://www.ariad.com/<br>
<br>
ARIAD is developing breakthrough medicines that regulate cell-signaling pathways implicated in cancer. ARIAD's pipeline includes a series of small molecule product candidates that provide targeted and highly potent anti-cancer activity to treat solid tumors and hematologic cancers, as well as the spread of tumors to distant sites. Our lead candidate &#x2014; deforolimus, a novel mTOR inhibitor &#x2014; has been given fast track designation by the FDA for the treatment of soft-tissue and bone sarcomas.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Founder and Initial CEO
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/neurocrine-biosciences?trk=ppro_cprof&amp;lnk=vw_cprofile" >Neurocrine Biosciences</a></h4>
  <p class="organization-details">(Public Company; 201-500 employees; NBIX; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1989">1989</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P20Y">(20 years )</abbr>
  </p>
    <p class="description">Original Founder and Initial CEO of this company<br>
<br>
http://www.neurocrine.com<br>
<br>
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine-related diseases. <br>
<br>
Neurocrine's product address  markets  including insomnia, anxiety, depression, irritable bowel syndrome and pain.<br>
<br>
Neurocrine currently has multiple programs in development. Several of these programs have advanced into clinical trials. Indiplon, for the treatment of insomnia, is being discussed with the FDA for resubmission for approval.  Neurocrine has completed a Phase II trial with GnRH  for the treatment of endometriosis  Neurocrine is evaluating its proprietary compound, urocortin 2 in a Phase II clinical development in patients with congestive heart failure. The Company's CRF program, partnered with GlaxoSmithKline, is continuing to develop multiple compounds in Phase I and Phase II clinical trials for anxiety/depression and irritable bowel syndrome (IBS).</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Founder and Initial CEO
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/metra?trk=ppro_cprof&amp;lnk=vw_cprofile" >Metra Biosystems</a></h4>
  <p class="organization-details">(Public Company; 501-1000 employees; QDEL; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1988">1988</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P21Y">(21 years )</abbr>
  </p>
    <p class="description">Original Founder and Initial CEO of this company that went public and was subsequently   acquired by Quidel<br>
<br>
http://www.quidel.com<br>
<br>
Quidel Corporation (Nasdaq: QDEL) is a leader serving to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Co-founder
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/vertex-pharmaceuticals?trk=ppro_cprof&amp;lnk=vw_cprofile" >Vertex Pharmaceuticals</a></h4>
  <p class="organization-details">(Public Company; 1001-5000 employees; VRTX; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1987">1987</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P22Y">(22 years )</abbr>
  </p>
    <p class="description">Co-founder of this company</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Co-founder
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/genpharm-inc%2E?trk=ppro_cprof&amp;lnk=vw_cprofile" >GenPharm International</a></h4>
  <p class="organization-details">(Privately Held; 11-50 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1986">1986</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P23Y">(23 years )</abbr>
  </p>
    <p class="description">Co-founder of GenPharm International and spinout company Pharming...GenPharm was acquired by Medarex</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      First Round Investor
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/viagen?trk=ppro_cprof&amp;lnk=vw_cprofile" >Viagene</a></h4>
  <p class="organization-details">(Privately Held; 51-200 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1986">1986</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P23Y">(23 years )</abbr>
  </p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      First Round Investor
    
      </h3>
      <h4 class="org summary">Gensia Pharmaceuticals</h4>
  <p class="organization-details">(Public Company; 51-200 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1986">1986</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P23Y">(23 years )</abbr>
  </p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Second Round Investor
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/idec?trk=ppro_cprof&amp;lnk=vw_cprofile" >IDEC Pharmaceuticals</a></h4>
  <p class="organization-details">(Privately Held; 1001-5000 employees; BIIB; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1986">1986</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P23Y">(23 years )</abbr>
  </p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      First Round Investor
    
      </h3>
      <h4 class="org summary">Biosym Technologies</h4>
  <p class="organization-details">(Privately Held; 51-200 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1986">1986</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P23Y">(23 years )</abbr>
  </p>
    <p class="description">First round investor in Biosym.<br>
<br>
Biosym was acquired by Corning for $250M.<br>
<br>
It was later spun out as Molecular Simulations and was subsequently acquired by Pharmacopeia. Pharmacopeia spun it out as Accelrys..<br>
<br>
Accelrys develops and commercializes Scientific Business Intelligence software for the integration, mining, analysis, modeling and simulation, management and interactive reporting of scientific data. Accelrys solutions are used by biologists, chemists, materials scientists, and information technology professionals for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today&#x2019;s leading research and development organizations.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      First Round Investor
    
      </h3>
      <h4 class="org summary">Cytotech</h4>
  <p class="organization-details">(Privately Held; 11-50 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1986">1986</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P23Y">(23 years )</abbr>
  </p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Co-founder
    
      </h3>
      <h4 class="org summary">Athena Neurosciences</h4>
  <p class="organization-details">(Public Company; 5001-10,000 employees; ELNCF; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1985">1985</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P24Y">(24 years )</abbr>
  </p>
    <p class="description">Original Founder  of this company that went public and was acquired by Elan Pharmaceuticals for $625 million.<br>
<br>
Athena Neuroscience is a pharmaceutical company committed to the field of neurology focusing on Alzheimer's disease.  Athena Neurosciences  went public under the stock symbol: ATHN and was subsequently acquired by Elan Corp for  $ 625M</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Husband
    
      </h3>
      <h4 class="org summary">The Bock Family</h4>
  <p class="organization-details">(Partnership; 1-10 employees; Professional Training &amp; Coaching industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1985">1985</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P24Y">(24 years )</abbr>
  </p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Second Round Investor
    
      </h3>
      <h4 class="org summary">GenProbe</h4>
  <p class="organization-details">(Public Company; 201-500 employees; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1985">1985</abbr>
 &mdash; <abbr class="dtstamp" title="2009-11-11">Present</abbr>        <abbr class="duration" title="P24Y">(24 years )</abbr>
  </p>
    <p class="description">Second Round investor in Gen Probe<br>
<br>
http://www.gen-probe.com<br>
<br>
Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 24 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      General Partner
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/avalon-ventures?trk=ppro_cprof&amp;lnk=vw_cprofile" >Avalon Ventures</a></h4>
  <p class="organization-details">(Partnership; 1-10 employees; Venture Capital &amp; Private Equity industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1988-06-01">June 1988</abbr>
 &mdash; <abbr class="dtend" title="1997-01-01">January 1997</abbr>        <abbr class="duration" title="P8Y8M">(8 years 8 months)</abbr>
  </p>
    <p class="description">De novo seed start-up venture capital fund and early stage investor in River Medical (Private &#x2013; drug delivery, purchased IVAC from Eli Lily in an LBO and did a $700M merger with IMED to form Alaris Medical (NASDAQ: AMI &#x2013; medical devices)),  Sequana Therapeutics  (NASDAQ: SQNA - genomics, merged with Arris Pharmaceuticals to form AXYS Pharmaceuticals (NASDAQ: AXPH) and subsequently acquired by Celera Genomics (NASDAQ: CRA)), Software Transformation (Private &#x2013; object based software programming, acquired by Novell (NASDAQ: NOVL) for $25M), Surface Logix (Private &#x2013; nano- imprint lithography), and Talarian (NASDAQ: TALR &#x2013; real time, high content information processing over distributed networks merged with TIBCO (NASDAQ: TIBX)).</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Associate
    
      </h3>
      <h4 class="org summary">Fairfield Ventures</h4>
  <p class="organization-details">(Partnership; 1-10 employees; Venture Capital &amp; Private Equity industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1985">1985</abbr>
 &mdash; <abbr class="dtend" title="1988">1988</abbr>        <abbr class="duration" title="P3Y">(3 years )</abbr>
  </p>
    <p class="description">Early stage venture investor in Biosym Technologies (Private &#x2013; computer-aided-drug discovery &#x2013; acquired by Corning (NYSE: GLW) for $250M))  Gen-Probe (NASDAQ: GNPR &#x2013; DNA diagnostics, acquired by Chugai Pharmaceuticals for $180M), Gensia Pharmaceuticals (NASDAQ: GNSA &#x2013; cardiovascular drugs, merged with Sicor to become Gensia-Sicor and subsequently acquired by TEVA Pharmaceuticals  (NASDAQ: TEVA)), IDEC Pharmaceuticals (NASDAQ: IDEC &#x2013; monoclonal antibody therapy, merged with Biogen to become Biogen Idec (NASDAQ: BIIB)), Oclassen Pharmaceuticals (Private - dermatology, acquired by Watson Pharmaceuticals (NYSE: WPI) for $180M), and  Viagene (Private &#x2013; gene therapy, acquired by Chiron Corporation for $100M).</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Summer Intern
    
      </h3>
      <h4 class="org summary">Burr, Egan and Deleage</h4>
  <p class="organization-details">(Partnership; 1-10 employees; Venture Capital &amp; Private Equity industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1984">1984</abbr>
 &mdash; <abbr class="dtend" title="1985">1985</abbr>        <abbr class="duration" title="P1Y">(1 year )</abbr>
  </p>
    <p class="description">Summer intern at this high technology venture capital fund</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Research Associate
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/genentech?trk=ppro_cprof&amp;lnk=vw_cprofile" >Genentech, Inc.</a></h4>
  <p class="organization-details">(Public Company; 10,001 or more employees; gene; Biotechnology industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1980">1980</abbr>
 &mdash; <abbr class="dtend" title="1983">1983</abbr>        <abbr class="duration" title="P3Y">(3 years )</abbr>
  </p>
    <p class="description">Started career as a Researcher in the early days at Genentech, Inc. in the field of infectious diseases, where he was on the team that received the AAAS Newcomb Cleveland Prize for demonstrating the world&#x2019;s first recombinant DNA vaccine.</p>
</li>



<li class="experience vevent vcard"> <a href="#name" class="include"></a>
      <h3 class="title">
        
      Student
    
      </h3>
      <h4 class="org summary"><a href="http://www.linkedin.com/companies/bowdoin-college?trk=ppro_cprof&amp;lnk=vw_cprofile" >Bowdoin College</a></h4>
  <p class="organization-details">(Educational Institution; 501-1000 employees; Higher Education industry)</p>
  <p class="period">
        <abbr class="dtstart" title="1977">1977</abbr>
 &mdash; <abbr class="dtend" title="1981">1981</abbr>        <abbr class="duration" title="P4Y">(4 years )</abbr>
  </p>
</li>
            </ul>
          </div>
          <hr />
          <div id="education">
            <h2>Larry Bock&#8217;s Education</h2>
            <ul class="vcalendar">


	<li class="education vevent vcard">
    <h3 class="summary fn org">
           University of California, Los Angeles - The Anderson School of Management
      </h3>
		<div class="description">
    <p>
      <span class="degree">MBA</span>
        , 
      <span class="major">Finance/Entrepreneurial Studies</span>
      , 
          <abbr class="dtstart" title="1982-01-01">1982</abbr> &mdash; <abbr class="dtend" title="1985-12-31">1985</abbr> 
    </p>
		<dl class="activities-societies">
			<dt>Activities and Societies:</dt>
			<dd>Entrepreneur Society, Venture Capital Fellows</dd>
		</dl>
		</div>
  </li>


	<li class="education vevent vcard">
    <h3 class="summary fn org">
           Horace Greeley High School
      </h3>
		<div class="description">
    <p>
      <span class="degree">HS</span>
        
      
      , 
          <abbr class="dtstart" title="1974-01-01">1974</abbr> &mdash; <abbr class="dtend" title="1982-12-31">1982</abbr> 
    </p>
		</div>
  </li>


	<li class="education vevent vcard">
    <h3 class="summary fn org">
           Bowdoin College
      </h3>
		<div class="description">
    <p>
      <span class="degree">BA</span>
        , 
      <span class="major">Biochemistry</span>
      , 
          <abbr class="dtstart" title="1977-01-01">1977</abbr> &mdash; <abbr class="dtend" title="1981-12-31">1981</abbr> 
    </p>
		<dl class="activities-societies">
			<dt>Activities and Societies:</dt>
			<dd>Molecular Biolog Society, Film Society, Outing Club</dd>
		</dl>
		</div>
  </li>
            </ul>
          </div>
          <hr />
          <div id="additional-information">
            <h2>Additional Information</h2>
              <h3>Larry Bock&#8217;s Websites:</h3>
              <ul class="websites">
                  <li>
<a href="http://www.youtube.com/watch?v=lF5B-539v-Q" class="url" rel="nofollow" target="_blank">UC Berkeley Commencement Addre</a>                  </li>
                  <li>
<a href="http://www.luxcapital.com/team_bock.php" class="url" rel="nofollow" target="_blank">Lux Capital</a>                  </li>
                  <li>
<a href="http://bowdoin.facebook.com/profile.php?id=721209637" class="url" rel="nofollow" target="_blank">FaceBook</a>                  </li>
              </ul>
              <h3>Larry Bock&#8217;s Interests:</h3>
              <p class="interests">nanotechnology, biotechnology, education, entrepreneurship, venture capital, skiing, whitewater kayaking, digital video editing, international travel</p>
              <h3>Larry Bock&#8217;s Groups:</h3>
                <p class="groups">
                  Advisory Board - NanoBusiness Alliance, Technology Advisory Board - NanoBusiness Alliance, Environmental Health and Safety Advisory Board NanoBusiness Alliance, President&#x2019;s Export Council Subcommittee on Export Administration  (PECSEA), Nanotechnology Technical Advisory Group (NTAG) reporting to the President&#x2019;s Council of Advisors on Science and Technology (PCAST), Blue Ribbon Task Force on Nanotechnology, Advisory Board of the Faculty of Chemistry at the University of California, Berkeley, Editorial Board of the Journal of Nano Education
                </p>
              <ul>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=32&amp;sharedKey=234080755622" >          <img src="http://media.linkedin.com/media/p/2/000/005/036/2ab2f57.jpg" width="60" height="30" alt="UCLA Anderson Alumni Network" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">UCLA Anderson Alumni Network</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=2877&amp;sharedKey=30950504D0B7" >          <img src="http://media.linkedin.com/media/p/1/000/000/009/261964b.gif" width="60" height="30" alt="On Startups - The Community For Entrepreneurs" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">On Startups - The Community For Entrepreneurs</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=54400&amp;sharedKey=1F5B8D681007" >          <img src="http://media.linkedin.com/media/p/3/000/004/303/1c41bba.png" width="60" height="30" alt="SoCal Science Cafe: Career Cafe" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">SoCal Science Cafe: Career Cafe</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=73744&amp;sharedKey=7FB5A67424AF" >          <img src="http://media.linkedin.com/media/p/2/000/01b/0f1/10a1609.png" width="60" height="30" alt="Genentech Employees and Alumni" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">Genentech Employees and Alumni</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=79179&amp;sharedKey=18AAC8135398" >          <img src="/img/groups/default/default_small.gif" width="60" height="30" alt="Small Cap Investors" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">Small Cap Investors</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=82733&amp;sharedKey=3808D83C97D8" >          <img src="http://media.linkedin.com/media/p/2/000/007/2f1/0fa53f9.png" width="60" height="30" alt="CleanTech Network" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">CleanTech Network</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=90792&amp;sharedKey=00B1D174A4C3" >          <img src="http://media.linkedin.com/media/p/1/000/035/323/0da44a9.png" width="60" height="30" alt="USA Science Festival" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">USA Science Festival</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=122300&amp;sharedKey=10DEA862D6E8" >          <img src="http://media.linkedin.com/media/p/3/000/00b/0d0/17f26b6.png" width="60" height="30" alt="Advanced Scientific Communities (TM)" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">Advanced Scientific Communities (TM)</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=127009&amp;sharedKey=34D014777116" >          <img src="http://media.linkedin.com/media/p/1/000/00b/275/22fccd8.png" width="60" height="30" alt="Mad4iPhone - The official iPhone users group -" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">Mad4iPhone - The official iPhone users group -</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=750257&amp;sharedKey=2940327E7F30" >          <img src="http://media.linkedin.com/media/p/1/000/00f/38d/1a00e9d.png" width="60" height="30" alt="STEM Development Coalition (STEM D.C.)" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">STEM Development Coalition (STEM D.C.)</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=883597&amp;sharedKey=0D9C501AE539" >          <img src="http://media.linkedin.com/media/p/3/000/011/220/246818c.png" width="60" height="30" alt="UC San Diego Entrepreneur Challenge" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">UC San Diego Entrepreneur Challenge</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=1189177&amp;sharedKey=6C041265C4E6" >          <img src="http://media.linkedin.com/media/p/3/000/015/010/2ce00be.png" width="60" height="30" alt="Bowdoin Career Advisory Network" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">Bowdoin Career Advisory Network</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=1209967&amp;sharedKey=0623243ED375" >          <img src="http://media.linkedin.com/media/p/3/000/02e/3bc/2e12632.png" width="60" height="30" alt="Pharmacopeia Inc. Alumni" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">Pharmacopeia Inc. Alumni</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=1895022&amp;sharedKey=4AAE5D4198CC" >          <img src="http://media.linkedin.com/media/p/1/000/026/02c/3ef3887.png" width="60" height="30" alt="CleanTALK San Diego" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">CleanTALK San Diego</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=1979364&amp;sharedKey=224A1E6DC179" >          <img src="http://media.linkedin.com/media/p/2/000/026/308/07bffd5.png" width="60" height="30" alt="CONNECT - Springboard" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">CONNECT - Springboard</span> </li>
                  <li class="affiliation vcard">
                        <a href="http://www.linkedin.com/groupInvitation?groupID=1986905&amp;sharedKey=4962B01AEA6E" >          <img src="http://media.linkedin.com/media/p/3/000/026/1d9/276adb9.png" width="60" height="30" alt="MySDscience - San Diego Science Network" class="logo" />
</a>&nbsp;&nbsp;
                    <span class="fn org">MySDscience - San Diego Science Network</span> </li>
              </ul>
              <h3>Larry Bock&#8217;s Honors:</h3>
              <p class="honors">
                Venture Capital Journal - Ten Most Influential Venture Capitalists, Red Herring - Top Ten Innovators, Forbes-Wolfe NanoReport - Number One Powerbroker in Nanotechnology, Ernst &amp; Young - Finalist for Entrepreneur of the Year, Small Times - Innovator of the Year and Top 3  Business Leaders of the Year, Einstein Award by the Jerusalem Foundation,  World Economic Forum Technology Pioneers Award, Red Herring Top 100,  Scientific American&#x2019;s Nifty Fifty, Science Magazine&#x2019;s Technology Breakthrough of the Year, World Technology Network&#x2019;s Leading Company in Material Science.
              </p>
          </div>
          <hr />
      <div id="contact-settings">
        <h2>Larry Bock&#8217;s Contact Settings</h2>
        <h3>Interested In:</h3>
        <ul>
            <li>
              career opportunities
            </li>
            <li>
              consulting offers
            </li>
            <li>
              new ventures
            </li>
            <li>
              job inquiries
            </li>
            <li>
              expertise requests
            </li>
            <li>
              business deals
            </li>
            <li>
              reference requests
            </li>
            <li>
              getting back in touch
            </li>
        </ul>
      </div>
      <hr />
      <div class="viewfull">
        <p><a href="http://www.linkedin.com/ppl/webprofile?vmi=&id=9739295&pvs=pp&authToken=_7_t&authType=name&locale=en_US&trk=ppro_viewmore&lnk=vw_pprofile" class="action" rel="nofollow"><span>View Full Profile</span></a></p>
      </div>
  </div>
  <div id="control" class="infobar">
    <div class="powered">
      <h3> Public profile powered by: <a href="/home?trk=ppro_pbli" ><img src="http://static01.linkedin.com/img/logos/logo_82x23.png" height="23" width="82" alt="LinkedIn" /></a>
      </h3>
      <p>Create a public profile: <strong>
        <a href="http://www.linkedin.com/ppl/webprofile?gwp=&id=9739295&pvs=pp&authToken=_7_t&authType=name&locale=en_US&trk=ppro_geturl&lnk=sign_in" rel="nofollow">Sign In</a>
        </strong> or <strong>
        <a href="http://www.linkedin.com/ppl/webprofile?gwp=&id=9739295&pvs=pp&authToken=_7_t&authType=name&locale=en_US&trk=ppro_joinnow&lnk=join_now" rel="nofollow">Join Now</a>
        </strong></p>
    </div>
      <div class="box" id="readmore">
        <div class="title">
          <h3>View Larry Bock&#8217;s full profile:</h3>
        </div>
        <div class="content">
          <ul>
            <li>See who you and <strong>Larry Bock</strong> know in common</li>
            <li>Get introduced to <strong>Larry Bock</strong></li>
            <li>Contact <strong>Larry Bock</strong> directly</li>
          </ul>
          <p class="btn">
            <a href="http://www.linkedin.com/ppl/webprofile?vmi=&id=9739295&pvs=pp&authToken=_7_t&authType=name&locale=en_US&trk=ppro_viewmore&lnk=vw_pprofile" class="action" rel="nofollow"><span>View Full Profile</span></a>
          </p>
        </div>
      </div>
    
    
    <div class="box" id="search">
      <div class="title">
        <h3><strong>Name Search:</strong></h3>
      </div>
      <div class="content">
        <p><strong>Search for people you know</strong> from over 50 million professionals already on LinkedIn.</p>
        <form name="searchForm" action="/pub/dir/" method="get">
          <p class="field"><span class="lbl">
            <label for="first">First Name</label>
            <br />
            </span>
            <input type="text" name="first" id="first" />
            &nbsp;&nbsp;<span class="lbl"><br />
            <label for="last">Last Name</label>
            <br />
            </span>
            <input type="text" name="last" id="last" />
          </p>
          <p class="example">
            <input class="btn-secondary" type="submit" name="search" value="Search"/> (example: <strong>
<a href="http://www.linkedin.com/pub/dir/Larry/Bock/?trk=ppro_find_others" >Larry Bock</a></strong>)
          </p>
        </form>
      </div>
    </div>

    
    <script type="text/javascript">
      var dbl_page = 'public_profile';
    </script>
    
      <script type="text/javascript" src="http://static.linkedin.com/scds/pprofile/build-502_6_2523-prod/js/ads.js"></script>
    
      <script type="text/javascript">
      /* <![CDATA[ */
      var google_keywords = null, google_ad_client = 'pub-2283433109277150', google_ad_width = 300, google_ad_height = 250, google_ad_format = '300x250_as';
        var dbl_src = "http://ad.doubleclick.net/adj/linkedin.dart/" + dbl_page + ";;tile=1;dcopt=ist;sz=300x250;" + encodeURIComponent('extra=null') + ";ord=" + Math.random() * 10000000000000000 +"?";
        document.write('<script src="' + dbl_src + '" type="text/javascript"><\/script>');
      /* ]]> */
      </script>
  </div>
</div>
<hr />







<div id="footer">
  <div class="wrapper">
    <div id="directory">
      <h3>LinkedIn member directory:</h3>
      <ol type="a">
        <li><a href="/directory/people/a.html" >a</a></li>
        <li><a href="/directory/people/b.html" >b</a></li>
        <li><a href="/directory/people/c.html" >c</a></li>
        <li><a href="/directory/people/d.html" >d</a></li>
        <li><a href="/directory/people/e.html" >e</a></li>
        <li><a href="/directory/people/f.html" >f</a></li>
        <li><a href="/directory/people/g.html" >g</a></li>
        <li><a href="/directory/people/h.html" >h</a></li>
        <li><a href="/directory/people/i.html" >i</a></li>
        <li><a href="/directory/people/j.html" >j</a></li>
        <li><a href="/directory/people/k.html" >k</a></li>
        <li><a href="/directory/people/l.html" >l</a></li>
        <li><a href="/directory/people/m.html" >m</a></li>
        <li><a href="/directory/people/n.html" >n</a></li>
        <li><a href="/directory/people/o.html" >o</a></li>
        <li><a href="/directory/people/p.html" >p</a></li>
        <li><a href="/directory/people/q.html" >q</a></li>
        <li><a href="/directory/people/r.html" >r</a></li>
        <li><a href="/directory/people/s.html" >s</a></li>
        <li><a href="/directory/people/t.html" >t</a></li>
        <li><a href="/directory/people/u.html" >u</a></li>
        <li><a href="/directory/people/v.html" >v</a></li>
        <li><a href="/directory/people/w.html" >w</a></li>
        <li><a href="/directory/people/x.html" >x</a></li>
        <li><a href="/directory/people/y.html" >y</a></li>
        <li><a href="/directory/people/z.html" >z</a></li>
        <li type="disc"><a href="/directory/people/@.html" >more</a></li>
      </ol>
      <h3>Browse members</h3>
      <p>
        <a href="/static?key=country_listing" >by country</a>
      </p>
    </div>

    <ul id="nav-legal">
      <li class="first"><a href="/redirect?url=http%3A%2F%2Fpress%2Elinkedin%2Ecom%2Fabout&urlhash=ONnW" >About LinkedIn</a></li>
      <li><a href="/static?key=privacy_policy&trk=hb_ft_priv" >Privacy Policy</a></li>
      
          <li><a href="/redirect?url=http%3A%2F%2Flinkedin%2Ecusthelp%2Ecom&urlhash=M-b0" target="_blank">Customer Service</a></li>
        
      <li><a href="http://talent.linkedin.com/?pin=tr02" >Recruiting Solutions</a></li>
      <li><a href="/static?key=advertising_info&trk=trk%3Dhb_ft_ads" >Advertising</a></li>
    </ul>
    <p id="copyright">Copyright &copy; 2009 LinkedIn Corporation. All rights reserved. </p>
  
    <p id="terms-of-use">
      Use of this site is subject to express <a href="/static?key=user_agreement&trk=ftr_useragre">terms of use</a>, which prohibit commercial use of this site. By continuing past this page, you agree to abide by these terms.
    </p>
  </div>
</div>





  
  
  
  
  
   

        <script type="text/javascript" src="http://static.linkedin.com/scds/concat/pprofile/build-502_6_2523-prod/js?f=lib%2Fyui%2F2.7.0%2Fyahoo-dom-event%2Fyahoo-dom-event&amp;f=js%2Fcore%2FDefine&amp;f=js%2Futil%2FHelps&amp;f=js%2Fpublic_profile&amp;f=js%2Fshowhide&amp;f=js%2Fcookies"></script>
    
<script type="text/javascript">
/* <![CDATA[ */
  if(typeof(i18n) == 'undefined') var i18n = {}; 
  i18n.TEXT_PLEASE_ENTER = "Please enter a first and last name.";
  showHide.init();

  var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
  document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
/* ]]> */
</script>
<script type="text/javascript">
/* <![CDATA[ */
var pageTracker = _gat._getTracker("UA-3242811-1");
pageTracker._initData();
pageTracker._linkedInMemberCookie = readCookie("visit"); 
pageTracker._linkedInUserType = (pageTracker._linkedInMemberCookie == "M") ? "user" : "guest";  
pageTracker._setVar(pageTracker._linkedInUserType);
    pageTracker._trackPageview("control_profiles");    
/* ]]> */
</script>


<script type="text/javascript" src="http://edge.quantserve.com/quant.js"></script> 
<noscript> 
  <a href="http://www.quantcast.com/p-b3sGjMtCFrexE" target="_blank"><img src="http://pixel.quantserve.com/pixel/p-b3sGjMtCFrexE.gif" style="display: none;" border="0" height="1" width="1" alt="Quantcast" /></a> 
</noscript>



<script type="text/javascript" src="http://b.scorecardresearch.com/beacon.js"></script> 
<script type="text/javascript">
  COMSCORE.beacon({ c1:2, c2:6402952, c3:"", c4:"", c5:"", c6:"", c15:"" });
</script>
<noscript> 
  <img src="http://b.scorecardresearch.com/b?c1=2&amp;c2=6402952&amp;c3=&amp;c4=&amp;c5=&amp;c6=&amp;c15=&amp;cv=1.3&amp;cj=1" style="display:none" width="0" height="0" alt="" />
</noscript>



</body>
</html>

